A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Chronic Phase With T315I Mutation

NCT03883087 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Myeloid Leukemia, Chronic Phase

Interventions

DRUG: HQP1351

Sponsor

Ascentage Pharma Group Inc.